C. Gómez-Arango

Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients.

M. González-Gay, E. Pérez-Pampín, E. de Miguel, 2021, Seminars in arthritis and rheumatism.

Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.

M. González-Gay, E. Pérez-Pampín, E. de Miguel, 2019, Seminars in arthritis and rheumatism.

Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial

D. Nagore, I. Gorostiza, J. Belzunegui, 2021, Rheumatology and Therapy.

THU0313 COMPARATIVE STUDY OF CLINICAL, ANALYTICAL AND VASCULAR 18F-FDG UPTAKE EVOLUTION IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH METHOTREXATE VS TOCILIZUMAB

M. González-Gay, E. Pérez-Pampín, S. Castañeda, 2019, Poster Presentations.

Efficacy of Anakinra in Refractory Adult-Onset Still's Disease

M. González-Gay, J. Llorca, P. Carreira, 2015, Medicine.

Identification of a 3′‐Untranslated Genetic Variant of RARB Associated With Carotid Intima‐Media Thickness in Rheumatoid Arthritis: A Genome‐Wide Association Study

Javier Martín, M. González-Gay, L. Rodríguez-Rodríguez, 2019, Arthritis & rheumatology.

Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.

M. González-Gay, E. Pérez-Pampín, E. de Miguel, 2020, Clinical and experimental rheumatology.

AB0577 TOCILIZUMAB IN GIANT CELL ARTERITIS. ROUTE OF ADMINISTRACION: INTRAVENOUS OR SUBCUTANEOUS

M. González-Gay, F. Navarro, S. Castañeda, 2019, Abstracts Accepted for Publication.